This joint Master's program will equip you with the necessary competencies to play a key role in the emerging field of transfusion medicine. Its current concept includes both transfusions of blood components and hematopoietic transplants, cellular and tissue therapy, and immunotherapy. Areas that are integrated into the curriculum of this Master's.
What does this Master’s program entail?
The Master's Transfusion Medicine and Cellular and Tissue Therapies (MT3) is a collaboration between Leiden University (LUMC) and the Autonomous University of Barcelona. By following this program, you will acquire and develop specific competencies in analyzing and applying the latest advances in transfusion medicine and cellular therapies. These include competencies related to donor management, technical-process design, identification of quality indicators, selection of blood components for clinical use, laboratory diagnosis, cellular therapies, and activities in support of scientific knowledge that are complementary to the teaching program.
Why choose MT3 at Leiden University and the Autonomous University of Barcelona?
This globally unique joint Master's is led by professors and reference authors that cover the most up-to-date knowledge possible in the area of transfusion medicine and cellular and tissue therapies.
The collaboration between the Autonomous University of Barcelona, Leiden University, Sanquin, and the Blood and Tissue Bank forms one of the most powerful international alliances for the creation and transmission of knowledge in the field.
The courses of the Master's program will be given completely online, which offers the possibility of following the learning process without needing to coincide in space or time. This gives you the flexibility to combine the program with other professional and personal responsibilities.